Nanotechnology Now





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > AparnaBio Introduces InVivoPlexTM –TUMOR Nanoparticle RNAi Delivery System

Abstract:
First Tumor Targeted Reagent For in vivo Gene Function Research using RNAi or Gene Delivery

AparnaBio Introduces InVivoPlexTM –TUMOR Nanoparticle RNAi Delivery System

Rockville, MD | Posted on May 20th, 2010

Aparna Biosciences announced the introduction of InVivoPlexTM -TUMOR, the first tumor targeted nanoparticle reagent for in vivo translation of RNAi gene function research to mouse models of cancer. This innovative nanoparticle reagent system was presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR), in Washington, DC, April 17-21, 2010.

The revolutionary capability of RNAi to selectively inhibit genes, recognized by a Nobel Prize, has led to explosive growth in understanding of tumor cell biology. To date RNAi based gene inhibition to identify potential new drug targets has largely involved in vitro experimentation. However, translation of this understanding into effective therapeutic strategies, validation of new targets for drug development, and highly selective therapeutics requires efficient in vivo delivery of RNAi agents in animal models. To address this need, AparnaBio has developed the InVivoPlexTM -TUMOR nanoparticle RNAi reagent. It targets RNAi activity in vivo to tumors via their leaky blood vessels and importantly minimizes RNAi activity at organs where effects can be toxic or obscure effects at the tumor.

InVivoPlexTM -TUMOR accelerates translation of research, an important stage in development of better treatments for cancer patients. InVivoPlexTM -TUMOR nanoparticle reagents are for research use only, but are based on AparnaBio's NanoElectroPlex TM clinically viable technology platform that is also being used to develop vaccines, therapeutics and imaging agents.

InVivoPlexTM -TUMOR development has been supported by funding from the National Institutes of Health and the State of Maryland, and funding for marketing and late stage product development by a Technology Growth Program grant from the Office of from Economic Development, Montgomery County, Maryland.

####

About AparnaBio
AparnaBio is a privately held, early stage biotech company located in Rockville, Maryland. The Company was founded in 2007 by Drs. Martin Woodle and Puthupparampil Scaria to develop advanced biomedical nanoparticles for in vivo research and tissue targeted therapeutics for treatment of cancer and other diseases. AparnaBio has established a proprietary technology platform, NanoElectroPlexTM, clinically viable nanoparticles for tissue targeted delivery for RNAi, gene therapy, and other agents with pharmacological properties that limit their therapeutic application. AparnaBio has attracted support from federal, state, and local governmental agents, including grants from NCI, NIAID, State of Maryland TEDCO and DBED, and Montgomery County.

AparnaBio’s InVivoPlexTM product family is based on the NanoElectroPlexTM proprietary technology platform for localization of nucleic acid agents at pathological tissues or specific cells associated with disease. AparnaBio is developing a portfolio of reagents for tissue targeted in vivo delivery. InVivoPlexTM –TUMOR, the first product released in this family, selectively delivers RNAi agents to vascularized tumors in mouse models of cancer. Development is ongoing to generate additional InVivoPlexTM products that provide ligand specific cell targeting. These reagents facilitate tissue selective target validation in animal models of disease, as well as RNAi drug discovery, and provide a foundation for development of tissue targeted RNAi nanoparticle therapeutics.

About RNAi
RNA interference (RNAi) is a revolutionary, robust and reproducible method to selectively inhibit genes, based on a natural mechanism for selective regulation of gene expression. RNAi reagents, short interfering RNA oligonucleotides (siRNA) and plasmid expressed hairpin RNA (shRNA and miRNA), have been adopted widely for research and have enabled a rapid growth in understanding of how genes are turned on and off in cells, and represent a new approach to drug discovery and development. RNAi offers the opportunity to discover critical biochemical pathways and regulatory factors underlying the pathology of disease, new targets for development of specific and highly selective medicines. Translation of RNAi from cell culture to in vivo animal models of cancer enables an essential step for advancing these discoveries to new therapeutics, and lays a foundation for therapeutic development of RNAi agents as a whole new class of highly specific therapeutics.

For more information, please click here

Contacts:
Mark Berninger, Vice President Business Development
12111 Parklawn Drive
Rockville, MD 20852-1707
1-301-770-2101

Copyright © AparnaBio

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Production of Zirconium Carbide Nanoparticles at Low Temperature without Thermal Operations July 5th, 2015

A 'movie' of ultrafast rotating molecules at a hundred billion per second: A quantum wave-like nature was successfully observed in rotating nitrogen molecules July 4th, 2015

New Biosensor Produced in Iran to Detect Effective Drugs in Cancer Treatment July 4th, 2015

Pioneering Southampton scientist awarded prestigious physics medal July 3rd, 2015

Govt.-Legislation/Regulation/Funding/Policy

New technology using silver may hold key to electronics advances July 2nd, 2015

NIST Group Maps Distribution of Carbon Nanotubes in Composite Materials July 2nd, 2015

NIST ‘How-To’ Website Documents Procedures for Nano-EHS Research and Testing July 1st, 2015

Ultra-stable JILA microscopy technique tracks tiny objects for hours July 1st, 2015

Nanomedicine

New Biosensor Produced in Iran to Detect Effective Drugs in Cancer Treatment July 4th, 2015

Groundbreaking research to help control liquids at micro and nano scales July 3rd, 2015

Iranian Scientists Find Simple, Economic Method to Synthesize Antibacterial Nanoparticles July 2nd, 2015

Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015

Announcements

Production of Zirconium Carbide Nanoparticles at Low Temperature without Thermal Operations July 5th, 2015

A 'movie' of ultrafast rotating molecules at a hundred billion per second: A quantum wave-like nature was successfully observed in rotating nitrogen molecules July 4th, 2015

New Biosensor Produced in Iran to Detect Effective Drugs in Cancer Treatment July 4th, 2015

Pioneering Southampton scientist awarded prestigious physics medal July 3rd, 2015

Events/Classes

Nanometrics to Announce Second Quarter Financial Results on July 23, 2015 July 2nd, 2015

Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015

How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems June 29th, 2015

Graphene breakthrough as Bosch creates magnetic sensor 100 times more sensitive than silicon equivalent June 28th, 2015

Nanobiotechnology

Groundbreaking research to help control liquids at micro and nano scales July 3rd, 2015

Engineering the world’s smallest nanocrystal July 2nd, 2015

Nanometric sensor designed to detect herbicides can help diagnose multiple sclerosis June 23rd, 2015

Newly-Developed Biosensor in Iran Detects Cocaine Addiction June 23rd, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project